Real-world experience and clinical utility of a non-invasive gene expression rule-out test for melanoma and additional validation against high risk driver mutations in BRAF, NRAS and the TERT promoter. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 2, p. S69, 2018. DOI: 10.25251/skin.2.supp.69. Disponível em: https://skin.dermsquared.com/skin/article/view/465. Acesso em: 8 jun. 2025.